Table 1 Measurement means
n | Mean ± SD | Min–Max (Median) | p | ||
|---|---|---|---|---|---|
Age (years) | ICP group | 175 | 28.52 ± 5.61 | 18–46 (28) | 0.718 |
Control group | 162 | 28.57 ± 4.98 | 18–43 (28) | ||
Weight (kg) | ICP group | 175 | 74.82 ± 11.22 | 48–110 (75) | 0.860 |
Control group | 162 | 74.73 ± 9.24 | 55–109 (75) | ||
Height (cm) | ICP group | 175 | 161.36 ± 4.81 | 145–172 (160) | 0.088 |
Control group | 162 | 162.43 ± 4.61 | 150–175 (162) | ||
Body Mass Index (kg/m2) | ICP group | 175 | 28.73 ± 4.13 | 19.83–44.54 (28.34) | 0.596 |
Control group | 162 | 28.29 ± 2.97 | 20.42–36.81 (27.68) | ||
Birth Week (Days) | ICP group | 175 | 253.75 ± 15.53 | 201–282 (259) | 0.001** |
Control group | 162 | 271.43 ± 10.26 | 231–289 (272) | ||
Fibrinogen (mg/dL) | ICP group | 175 | 574.92 ± 115.22 | 154–894 (580) | 0.001** |
Control group | 162 | 494.87 ± 89.56 | 287–743 (488) | ||
Prepartum Hematocrit (%) | ICP group | 175 | 33.89 ± 4.16 | 22.3–47.7 (33.9) | 0.985 |
Control group | 162 | 33.9 ± 3.57 | 25.2–46.4 (33.95) | ||
Postpartum Hematocrit (%) | ICP group | 175 | 30.34 ± 3.29 | 22.1–40.1 (30.5) | 0.834 |
Control group | 162 | 30.64 ± 1.78 | 20.1–38 (30.5) | ||
Platelets (109/L) | ICP group | 175 | 250.81 ± 72.39 | 39–476 (239) | 0.094 |
Control group | 162 | 235.76 ± 59.78 | 52–429 (232) | ||
Albumin (g/L) | ICP group | 175 | 34.29 ± 5.28 | 23–50 (34) | 0.001** |
Control group | 162 | 40.2 ± 6.36 | 27–48 (41) | ||
Total Protein (g/L) | ICP group | 175 | 64.59 ± 7.45 | 48–79 (65) | 0.428 |
Control group | 162 | 66.43 ± 7.69 | 52–78 (65) | ||
aPTT (sec) | ICP group | 175 | 26.94 ± 4.12 | 16.6–51 (26.6) | 0.521 |
Control group | 162 | 26.95 ± 3.08 | 18.7–44.6 (27) | ||
INR | ICP group | 175 | 0.89 ± 0.14 | 0.7–1.9 (0.9) | 0.001** |
Control group | 162 | 0.9 ± 0.11 | 0.44–1.8 (0.9) | ||
LDH (U/L) | ICP group | 175 | 252.86 ± 75.24 | 123–637 (237) | 0.001** |
Control group | 162 | 216.36 ± 70.87 | 127–614 (200) | ||
ALT (U/L) | ICP group | 175 | 120.15 ± 156.82 | 3-1022 (67) | 0.001** |
Control group | 162 | 11.06 ± 6.27 | 2–46 (10) | ||
GGT (U/L) | ICP group | 175 | 26.76 ± 33.27 | 4-297 (16) | 0.001** |
Control group | 162 | 11.89 ± 9.44 | 4–54 (8) | ||
AST (U/L) | ICP group | 175 | 83.97 ± 94.36 | 9-690 (52) | 0.001** |
Control group | 162 | 14.87 ± 5.92 | 4–46 (14) | ||
ALP (U/L) | ICP group | 175 | 206.04 ± 81.66 | 40–463 (203) | 0.001** |
Control group | 162 | 120.3 ± 75.51 | 46–414 (109) | ||
Total bilurubin (mg/dL) | ICP group | 175 | 0.65 ± 0.65 | 0.09–4.5 (0.48) | 0.001** |
Control group | 162 | 0.38 ± 0.19 | 0.13–0.81 (0.35) | ||
Direct bilurubin (mg/dL) | ICP group | 175 | 0.43 ± 0.43 | 0.04–3.7 (0.3) | 0.001** |
Control group | 162 | 0.16 ± 0.07 | 0.06–0.31 (0.15) | ||
Eosinophils (109/L) | ICP group | 175 | 0.08 ± 0.08 | 0-0.7 (0.06) | 0.977 |
Control group | 162 | 0.09 ± 0.1 | 0-0.74 (0.06) | ||
Basophils (109/L) | ICP group | 175 | 0.03 ± 0.03 | 0-0.4 (0.02) | 0.001** |
Control group | 162 | 0.03 ± 0.06 | 0-0.69 (0.02) | ||
Lymphocytes (109/L) | ICP group | 175 | 1.29 ± 0.46 | 0.61–3.9 (1.12) | 0.001** |
Control group | 162 | 1.95 ± 0.57 | 0.67–5.29 (1.93) | ||
Urea (mg/dL) | ICP group | 175 | 16.39 ± 7.24 | 1.9–55.3 (14.85) | 0.443 |
Control group | 162 | 15.16 ± 5.17 | 1.8–31.9 (14.6) | ||
Creatinine (mg/dL)) | ICP group | 175 | 0.54 ± 0.14 | 0.23–1.2 (0.52) | 0.430 |
Control group | 162 | 0.53 ± 0.1 | 0.3–0.9 (0.51) | ||
Gfr (mL/min/1, 73m2) | ICP group | 175 | 127.76 ± 15.29 | 34–163 (129) | 0.428 |
Control group | 162 | 129.76 ± 9.99 | 99–163 (130) | ||
Birth APGAR-1 | ICP group | 175 | 7.25 ± 1.32 | 1–9 (8) | 0.064 |
Control group | 162 | 7.58 ± 0.89 | 4–9 (8) | ||
Birth APGAR-5 Gfr (mL/min/1, 73m2) | ICP group | 175 | 8.49 ± 1.12 | 2–10 (9) | 0.001** |
Control group | 162 | 8.84 ± 0.65 | 6–10 (9) | ||
Duration of Hospitalization (Days) | ICP group | 175 | 7.4 ± 8.17 | 2–64 (5) | 0.001** |
Control group | 162 | 2.11 ± 1.28 | 2–17 (2) |